Recent Analyst Stock Rating News
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.Get Started for Free
Keith Tapper's Stock Ratings
BMO Capital Analyst
Keith Tapper is an analyst at BMO Capital. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 06/22/2025
Overall Average Return
11.1%
Smart Score
Overall Average Return Percentile
64th
| Buy Now | Get Alert | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 04/14/2025 | NGNE | Buy Now | Neurogene | $17.76 | -9.91% | Keith Tapper57% | $45 → $16 | Maintains | Outperform | Get Alert |
| 11/20/2024 | NGNE | Buy Now | Neurogene | $17.76 | 153.38% | Keith Tapper57% | $60 → $45 | Maintains | Outperform | Get Alert |
| 11/12/2024 | NGNE | Buy Now | Neurogene | $17.76 | 237.84% | Keith Tapper57% | $65 → $60 | Maintains | Outperform | Get Alert |
| 06/27/2024 | TSHA | Buy Now | Taysha Gene Therapies | $2.42 | 106.61% | Keith Tapper57% | → $5 | Initiates | → Outperform | Get Alert |
| 06/27/2024 | ACAD | Buy Now | ACADIA Pharmaceuticals | $22.71 | 36.5% | Keith Tapper57% | → $31 | Initiates | → Outperform | Get Alert |
| 06/27/2024 | NGNE | Buy Now | Neurogene | $17.76 | 265.99% | Keith Tapper57% | → $65 | Initiates | → Outperform | Get Alert |
